Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt No Debt
NYMX's Cash to Debt is ranked higher than
97% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. NYMX: No Debt )
NYMX' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: No Debt

Equity to Asset -5.24
NYMX's Equity to Asset is ranked lower than
52% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NYMX: -5.24 )
NYMX' s 10-Year Equity to Asset Range
Min: -7.82   Max: 1
Current: -5.24

-7.82
1
F-Score: 2
Z-Score: -164.59
M-Score: -6.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -170.20
NYMX's Operating margin (%) is ranked higher than
68% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. NYMX: -170.20 )
NYMX' s 10-Year Operating margin (%) Range
Min: -20470.59   Max: -145.43
Current: -170.2

-20470.59
-145.43
Net-margin (%) -171.56
NYMX's Net-margin (%) is ranked higher than
68% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. NYMX: -171.56 )
NYMX' s 10-Year Net-margin (%) Range
Min: -20570.59   Max: -146.14
Current: -171.56

-20570.59
-146.14
ROA (%) -584.34
NYMX's ROA (%) is ranked lower than
52% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. NYMX: -584.34 )
NYMX' s 10-Year ROA (%) Range
Min: -557.61   Max: -71.12
Current: -584.34

-557.61
-71.12
ROC (Joel Greenblatt) (%) -43346.77
NYMX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. NYMX: -43346.77 )
NYMX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -52027.03   Max: -155.56
Current: -43346.77

-52027.03
-155.56
Revenue Growth (3Y)(%) 71.00
NYMX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. NYMX: 71.00 )
NYMX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 115.4
Current: 71

0
115.4
EBITDA Growth (3Y)(%) -11.20
NYMX's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NYMX: -11.20 )
NYMX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.6   Max: 24.6
Current: -11.2

-20.6
24.6
EPS Growth (3Y)(%) -11.20
NYMX's EPS Growth (3Y)(%) is ranked higher than
75% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. NYMX: -11.20 )
NYMX' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.6   Max: 23.3
Current: -11.2

-17.6
23.3
» NYMX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NYMX Guru Trades in Q4 2013

Jim Simons 43,300 sh (+21.97%)
» More
Q1 2014

NYMX Guru Trades in Q1 2014

Jim Simons 26,506 sh (-38.79%)
» More
Q2 2014

NYMX Guru Trades in Q2 2014

Jim Simons 28,000 sh (+5.64%)
» More
Q3 2014

NYMX Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYMX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-09-30 Sold Out 0.0036%$5.9 - $6.88 $ 0.64-90%0
George Soros 2012-06-30 New Buy$6.5 - $8.39 $ 0.64-92%38400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 8.80
NYMX's P/S is ranked higher than
86% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. NYMX: 8.80 )
NYMX' s 10-Year P/S Range
Min: 3.68   Max: 729
Current: 8.8

3.68
729
EV-to-EBIT -4.30
NYMX's EV-to-EBIT is ranked higher than
50% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NYMX: -4.30 )
NYMX' s 10-Year EV-to-EBIT Range
Min: -47.5   Max: -2.2
Current: -4.3

-47.5
-2.2
Current Ratio 0.21
NYMX's Current Ratio is ranked lower than
52% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. NYMX: 0.21 )
NYMX' s 10-Year Current Ratio Range
Min: 0.12   Max: 42.02
Current: 0.21

0.12
42.02
Quick Ratio 0.20
NYMX's Quick Ratio is ranked lower than
51% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. NYMX: 0.20 )
NYMX' s 10-Year Quick Ratio Range
Min: 0.09   Max: 42.02
Current: 0.2

0.09
42.02
Days Inventory 40.47
NYMX's Days Inventory is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NYMX: 40.47 )
NYMX' s 10-Year Days Inventory Range
Min: 8.39   Max: 178.05
Current: 40.47

8.39
178.05
Days Sales Outstanding 6.59
NYMX's Days Sales Outstanding is ranked higher than
97% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. NYMX: 6.59 )
NYMX' s 10-Year Days Sales Outstanding Range
Min: 3.68   Max: 997.76
Current: 6.59

3.68
997.76

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.04
NYMX's Price/Median PS Value is ranked higher than
99% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. NYMX: 0.04 )
NYMX' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 2.88
Current: 0.04

0.24
2.88
Earnings Yield (Greenblatt) -18.90
NYMX's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NYMX: -18.90 )
NYMX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -40   Max: 0
Current: -18.9

-40
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NY2.Germany,
Nymox Pharmaceutical Corp was incorporated under the Canada Business Corporations Act in May 1995. The Company is a biopharmaceutical corporation engaged in research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease. It has three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as BPH, prostate cancer, Alzheimer's disease or AD, E. coli O157; H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's products include: NicAlert, TobacAlert and AlzheimAlert. The Company has developed and markets NicAlert and TobacAlert, test strips for determining whether a person is using tobacco products or has been recently exposed to second-hand smoke. It has also developed AlzheimAlert, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer's disease. The Company is also developing NX-1207, treatments for BPH and prostate and liver cancer. It is also developing NXC-4720, novel antibacterial agents for the treatment of E. coli O157 bacterial contamination in meat and other food and drink products. Its AlzheimAlert test is certified with a CE Mark, making the device eligible for sale in the European Union. The Company's competitors include: Eli Lilly and Company, GE Healthcare, Athena Diagnostics, Inc., Fujirebio Europe NV, Amorfix Life Sciences Ltd, LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott and Diagnostic Products Corporation.
» More Articles for NYMX

Headlines

Articles On GuruFocus.com
NYMOX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and K Jan 23 2015 
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceut Dec 02 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Nymox Pharmaceutical Dec 01 2014 

More From Other Websites
NYMOX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and... Jan 23 2015
UPDATE – UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox... Jan 20 2015
NYMOX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Jan 19 2015
UPDATE -- UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox... Jan 12 2015
Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important January 26, 2015... Jan 12 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox... Jan 02 2015
The Worst-Performing Biotech Stocks Of 2014 Jan 01 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Dec 30 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox... Dec 29 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Dec 22 2014
Nymox Announces $1.07 Million Financing Dec 18 2014
EQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class... Dec 12 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox... Dec 11 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Dec 09 2014
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Dec 08 2014
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc.,... Dec 04 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox... Dec 02 2014
Robbins Arroyo LLP: Nymox Pharmaceutical Corporation (NYMX) Misled Shareholders According to a... Dec 01 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Dec 01 2014
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Nymox Pharmaceutical... Dec 01 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK